


DID YOU KNOW?




of patients with MASLD presenting with normal liver enzymes are **underdiagnosed**



Up to 56% - of MASLD patients especially in the presence of type 2 diabetes **develop MASH**



More than 3 in 5 MASLD patients present with normal liver enzymes




Liver ultrasound is **unable to stage** liver fibrosis


How can LIVERFAST help?

LIVERFAST™


1 blood draw ▶ 3 scores



Fibrosis
0.41
F2
advanced fibrosis



Activity
0.43
A3
marked activity



Steatosis
0.63
S3
marked steatosis (≥67%)

Noninvasive test (NIT) for complete and immediate liver evaluation

Stages liver injury for common chronic liver diseases

- Metabolic Dysfunction-Associated Steatotic Liver Disease (MAFLD) / Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Alcoholic liver disease (ALD)
- Chronic Hepatitis C (CHC)
- Chronic Hepatitis B (CHB)

10 Biomarkers including Liver specific proteins, plus age, gender, and BMI

- Alpha-2-Macroglobulin
- Haptoglobin
- Apolipoprotein A1
- Total Bilirubin
- GGT
- ALT
- AST
- Fasting Glucose
- Tryglicerides
- Total Cholesterol

Early detection for proactive care and early health

Specificity for the specialist, **clarity** for the generalist, **easy to do** for everyone

Suitable for all use cases



Screening
Liver specific

- ✓ Specialist
- ✓ Generalist



Staging
Early to late staging

- ✓ Specialist
- ✓ Generalist



Monitoring
Easily repeatable

- ✓ Specialist



Prognosing
Patient outcomes and management

- ✓ Specialist

At risk population to screen for MASLD



Obesity



Diabetes



Hypertension



Dyslipidemia



OSA*



Bariatric Surgery



PCOS*

Simple and Easy to do



Physician prescribes **LIVERFAST™** for the patient



Lab analyzes 10 biomarkers from **1 blood sample**



Biomarker values plus **age, height, weight, gender**, are entered into the **LIVERFAST** platform



LIVERFAST™ results are **available immediately**

Test id: 45843
Reference no: GLJ021031108907


PATIENT NAME:

Physician Name

JOHN DOE M.D., P.A.

Patient ID	Gender	Date of Birth	Test Date	Blood Sample Date
B24678654	Female	1964-06-15	2024-07-17	2024-07-10

TEST SCORES



INTERPRETATION

S3-A3-F2

Your result for the SAF score is S3-A3-F2. This score indicates that you have marked steatosis (≥67%), marked activity and advanced fibrosis. Consult your physician for further evaluation.

BIOMARKER VALUES

Age: 60 years Height: 5 ft, 5 in Weight: 182 lbs BMI: *30.29

	Result	Unit		Result	Unit
Alpha-2-Macroglobulin	130	mg/dL	ALT	36	IU/L
Haptoglobin	187	mg/dL	AST	49	IU/L
Apolipoprotein A1	119	mg/dL	Fasting Glucose	97	mg/dL
Total Bilirubin	0.4	mg/dL	Total Cholesterol	161	mg/dL
GGT	42	IU/L	Triglycerides	198	mg/dL

* NOTE: The highlighted value is at the extremes of the acceptable range of biomarker values.

The performance characteristics of this test were determined by Stone Diagnostics. This test is not FDA approved/cleared. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. Results are not for use as the sole means for clinical diagnosis or patient management. M. Carmen Frias Kletecka, MD - Lab Director | Stone Diagnostics | 315 Serenoa Road, Ste A, Santa Rosa Beach, FL, 32459, USA | Tel: 844-786-6325 | Fax: 850-635-0638 | CLIA # 10D2161865




This report is computer generated. No signature required. LIVERFAST 1.3.0(240711_EN)



LIVERFAST™, the best screening tool that also stages liver fibrosis, steatosis & inflammatory activity

LIVERFAST™ predicts biopsy results, ALT and AST do not

Overall MASLD population (n=374*)



*deLedinghen V. et al. Hepatology Suppl 2020

LIVERFAST™ outperforms ELF, FIB-4 and Fibrotest as a MASH patient screening NIT

	LIVERFAST™	ELF	FIB-4	Fibrotest
Fibrosis Yes/No	YES	YES	YES	YES
Fibrosis Staging	YES	NO	NO	YES
Activity Staging	YES	NO	NO	NO
Steatosis Staging	YES	NO	NO	NO
Grey-zone	NO	YES	YES	NO
Easy to do	YES	NO	YES	YES
Works in ≥65yrs & T2D	YES	YES	NO	NO

- **LIVERFAST™ stages fibrosis from F0 to F4**
- **Gives complete liver staging for fibrosis, steatosis & activity in one test**
- **Does not miss F2 or F3 patients because of a "grey zone"**
- **Identifies twice as many F2 or F3 patients than FIB-4**
- **Works better in elderly & T2D**
- **Clinical Path Ready - LIVERFAST™ is ideal first step with Fibroscan**
- **Great for Screening - Identifies more target patients more easily in any setting than other NITs**

Contact Us
service@fibronostics.com

References:

1. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. *Curr Hypertens Rep.* 2018 Feb 26;20(2):12.
2. Paloma, A.V. et al. "Metabolic syndrome and non-alcoholic fatty liver disease". *Ann Hepatol* 2009;8 Suppl 1:518-24.
3. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology.* 2016 Jul;64(1):73-84.
4. Decraecker M, Dutartre D, Hiriart JB, Irlés-Depé M, Chermak F, Foucher J, de Ledinghen V. Long-term prognosis of patients with metabolic (dysfunction)-associated fatty liver disease by non-invasive methods. *Aliment Pharmacol Ther.* 2022 Mar;55(5):580-592.
5. Mohamad Nor MH, Ayob N, Mokhtar NM, Raja Ali RA, Tan GC, Wong Z, Shafiee NH, Wong YP, Mustangin M, Nawawi KNM. The Effect of Probiotics (MCP® BCMC® Strains) on Hepatic Steatosis, Small Intestinal Mucosal Immune Function, and Intestinal Barrier in Patients with Non-Alcoholic Fatty Liver Disease. *Nutrients.* 2021 Sep 14;13(9):3192.

* Abbreviations

- ALT** Alanine aminotransferase
AST Aspartate aminotransferase
GGT Gamma Glutamyl Transpeptidase
OSA Obstructive sleep apnea
PCOS Polycystic ovary syndrome
MASLD Metabolic Dysfunction-Associated Steatotic Liver Disease
MASH Metabolic Dysfunction-Associated Steatohepatitis
SLD Steatotic liver disease



FIBRONOSTICS US, INC.
274 E. Eau Gallie Blvd.
#346, Indian Harbour Beach, FL 32937

For more information, please visit
www.fibronostics.com



FIB-USA-LF-PCP-BRO_00